Plasma lipoproteins: genetic influences and clinical implications.
Susceptibility to the growing global public health problem of cardiovascular disease is associated with levels of plasma lipids and lipoproteins. Several experimental strategies have helped us to clarify the genetic architecture of these complex traits, including classical studies of monogenic dyslipidaemias, resequencing, phenomic analysis and, more recently, genome-wide association studies and analysis of metabolic networks. The genetic basis of plasma lipoprotein levels can now be modelled as a mosaic of contributions from multiple DNA sequence variants, both rare and common, with varying effect sizes. In addition to filling gaps in our understanding of plasma lipoprotein metabolism, the recent genetic advances will improve our ability to classify, diagnose and treat dyslipidaemias.
Hegele
Robert A
RA
Robarts Research Institute and Schulich School of Medicine and Dentistry, University of Western Ontario, 406-100 Perth Drive, London, Ontario, Canada N6A 5K8. hegele@robarts.ca
D000818:Animals; D002784:Cholesterol / Q000097:blood; D050171:Dyslipidemias / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D023281:Genomics; D006801:Humans; D006951:Hyperlipoproteinemias / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D008074:Lipoproteins / Q000097:blood / Q000235:genetics* / Q000378:metabolism*; D008954:Models, Biological; D014280:Triglycerides / Q000097:blood
D008074:Lipoproteins; D014280:Triglycerides; D002784:Cholesterol